1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

UK To Speed New COVID-19 Drug Candidates Into Trials

Collaborative Project Hailed As ‘Transformative’

 
• By Ian Schofield

The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19. 

Coronavirus
New COVID-19 candidates are entering trials under a UK initiative • Source: Shutterstock

The UK has launched a new initiative to accelerate the testing of potential new therapies for COVID-19, under which the time taken to set up clinical trials would be reduced “from months to just weeks,” according to the Department of Health and Social Care (DHSC).

Funded by the DHSC and UK Research and Innovation (UKRI), the Accelerating COVID-19 Research & Development (ACCORD) study is a multicenter, Phase II adaptive randomized platform trial that aims to provide an early indication of the effectiveness of drugs in treating the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

More from Europe